PE20151907A1 - Compuestos y usos de estos para la modulacion de la hemoglobina - Google Patents
Compuestos y usos de estos para la modulacion de la hemoglobinaInfo
- Publication number
- PE20151907A1 PE20151907A1 PE2015001920A PE2015001920A PE20151907A1 PE 20151907 A1 PE20151907 A1 PE 20151907A1 PE 2015001920 A PE2015001920 A PE 2015001920A PE 2015001920 A PE2015001920 A PE 2015001920A PE 20151907 A1 PE20151907 A1 PE 20151907A1
- Authority
- PE
- Peru
- Prior art keywords
- hemoglobin
- compounds
- ring
- modulation
- methods
- Prior art date
Links
- 102000001554 Hemoglobins Human genes 0.000 title abstract 3
- 108010054147 Hemoglobins Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000287 tissue oxygenation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/815,776 US9458139B2 (en) | 2013-03-15 | 2013-03-15 | Compounds and uses thereof for the modulation of hemoglobin |
| US201361905802P | 2013-11-18 | 2013-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151907A1 true PE20151907A1 (es) | 2016-01-20 |
Family
ID=51580734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015001920A PE20151907A1 (es) | 2013-03-15 | 2014-03-10 | Compuestos y usos de estos para la modulacion de la hemoglobina |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2970315B1 (OSRAM) |
| JP (2) | JP6401772B2 (OSRAM) |
| KR (1) | KR20150132147A (OSRAM) |
| CN (1) | CN105209469A (OSRAM) |
| AP (1) | AP2015008720A0 (OSRAM) |
| AU (1) | AU2014237361A1 (OSRAM) |
| BR (1) | BR112015021980A2 (OSRAM) |
| CA (1) | CA2902721C (OSRAM) |
| EA (1) | EA201591427A1 (OSRAM) |
| ES (1) | ES2909634T3 (OSRAM) |
| IL (1) | IL240845A0 (OSRAM) |
| MX (1) | MX388013B (OSRAM) |
| PE (1) | PE20151907A1 (OSRAM) |
| SG (1) | SG11201507351PA (OSRAM) |
| TW (1) | TW201518286A (OSRAM) |
| UY (1) | UY35425A (OSRAM) |
| WO (1) | WO2014150289A1 (OSRAM) |
| ZA (1) | ZA201506390B (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6242810B2 (ja) | 2011-12-28 | 2017-12-06 | グローバル・ブラッド・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｌｏｏｄ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 置換ベンズアルデヒド化合物および組織酸素化の増加におけるそれらの使用方法 |
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| SG11201507320QA (en) | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| ES2993155T3 (en) | 2013-03-15 | 2024-12-23 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| SG11201507453VA (en) | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| PL3102208T5 (pl) | 2014-02-07 | 2024-10-14 | Global Blood Therapeutics, Inc. | Krystaliczny polimorf wolnej zasady 2-hydroksy-6-((2-(1-izopropylo-1h-pirazol-5-ilo)pirydyn-3-ylo)metoksy)benzaldehydu |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| RU2018117889A (ru) | 2015-10-16 | 2019-11-20 | Эббви Инк. | СПОСОБЫ ПОЛУЧЕНИЯ (3S,4R)-3-ЭТИЛ-4-(3H-ИМИДАЗО[1,2-a]ПИРРОЛО[2,3-e]-ПИРАЗИН-8-ИЛ)-N-(2,2,2-ТРИФТОРЭТИЛ)ПИРРОЛИДИН-1-КАРБОКСАМИДА И ЕГО ТВЕРДОФАЗНЫХ ФОРМ |
| ES3039236T3 (en) | 2015-12-04 | 2025-10-20 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
| US10787430B2 (en) | 2016-06-17 | 2020-09-29 | Fronthera U.S. Pharmaceuticals Llc | Hemoglobin modifier compounds and uses thereof |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
| MD3880654T2 (ro) * | 2018-11-19 | 2022-05-31 | Global Blood Therapeutics Inc | Compuși 2-formil-3-hidroxifeniloximetilici capabili de modularea hemoglobinei |
| BR112021009057A2 (pt) | 2018-11-29 | 2021-08-10 | Pfizer Inc. | pirazóis como moduladores de hemoglobina |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0054924B1 (en) * | 1980-12-18 | 1986-08-06 | The Wellcome Foundation Limited | Pharmaceutical compounds, their preparation and use |
| FR2680512B1 (fr) * | 1991-08-20 | 1995-01-20 | Adir | Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| AU668818B2 (en) * | 1993-04-07 | 1996-05-16 | Taiho Pharmaceutical Co., Ltd. | Thiazolidine derivative and pharmaceutical composition containing the same |
| JP2000514041A (ja) * | 1996-07-26 | 2000-10-24 | ドクター・レディーズ・リサーチ・ファウンデーション | 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物 |
| US6184228B1 (en) * | 1999-05-25 | 2001-02-06 | Anadys Pharmaceuticals, Inc. | Anti-sickling agents: selection methods and effective compounds |
| AUPQ105499A0 (en) * | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
| US20030022923A1 (en) * | 2001-03-01 | 2003-01-30 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
| EP1567490B1 (en) * | 2002-12-04 | 2011-10-05 | Virginia Commonwealth University | Anti-sickling agents |
| CN1913896B (zh) * | 2003-12-02 | 2010-12-01 | 细胞基因公司 | 用于治疗和控制血红蛋白病和贫血病的方法和组合物 |
| DE102008027574A1 (de) * | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
| US20120122928A1 (en) * | 2010-08-11 | 2012-05-17 | Bayer Cropscience Ag | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides |
| JP6242810B2 (ja) * | 2011-12-28 | 2017-12-06 | グローバル・ブラッド・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｌｏｏｄ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 置換ベンズアルデヒド化合物および組織酸素化の増加におけるそれらの使用方法 |
| ES2993155T3 (en) * | 2013-03-15 | 2024-12-23 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
-
2014
- 2014-03-10 WO PCT/US2014/022846 patent/WO2014150289A1/en not_active Ceased
- 2014-03-10 MX MX2015011509A patent/MX388013B/es unknown
- 2014-03-10 AP AP2015008720A patent/AP2015008720A0/xx unknown
- 2014-03-10 JP JP2016501086A patent/JP6401772B2/ja active Active
- 2014-03-10 SG SG11201507351PA patent/SG11201507351PA/en unknown
- 2014-03-10 BR BR112015021980A patent/BR112015021980A2/pt not_active IP Right Cessation
- 2014-03-10 AU AU2014237361A patent/AU2014237361A1/en not_active Abandoned
- 2014-03-10 ES ES14768414T patent/ES2909634T3/es active Active
- 2014-03-10 CA CA2902721A patent/CA2902721C/en active Active
- 2014-03-10 EP EP14768414.6A patent/EP2970315B1/en active Active
- 2014-03-10 EA EA201591427A patent/EA201591427A1/ru unknown
- 2014-03-10 CN CN201480013378.3A patent/CN105209469A/zh active Pending
- 2014-03-10 PE PE2015001920A patent/PE20151907A1/es not_active Application Discontinuation
- 2014-03-10 KR KR1020157024775A patent/KR20150132147A/ko not_active Withdrawn
- 2014-03-13 UY UY35425A patent/UY35425A/es not_active Application Discontinuation
- 2014-03-13 TW TW103108889A patent/TW201518286A/zh unknown
-
2015
- 2015-08-26 IL IL240845A patent/IL240845A0/en unknown
- 2015-09-01 ZA ZA2015/06390A patent/ZA201506390B/en unknown
-
2018
- 2018-09-07 JP JP2018167981A patent/JP2018188481A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015021980A2 (pt) | 2017-07-18 |
| WO2014150289A1 (en) | 2014-09-25 |
| KR20150132147A (ko) | 2015-11-25 |
| UY35425A (es) | 2014-10-31 |
| EP2970315B1 (en) | 2021-09-15 |
| MX2015011509A (es) | 2016-05-31 |
| CA2902721C (en) | 2021-09-14 |
| TW201518286A (zh) | 2015-05-16 |
| AU2014237361A1 (en) | 2015-09-17 |
| MX388013B (es) | 2025-03-19 |
| CA2902721A1 (en) | 2014-09-25 |
| EA201591427A1 (ru) | 2016-01-29 |
| SG11201507351PA (en) | 2015-10-29 |
| JP6401772B2 (ja) | 2018-10-10 |
| EP2970315A4 (en) | 2016-08-17 |
| IL240845A0 (en) | 2015-10-29 |
| ZA201506390B (en) | 2017-03-29 |
| EP2970315A1 (en) | 2016-01-20 |
| CN105209469A (zh) | 2015-12-30 |
| ES2909634T3 (es) | 2022-05-09 |
| JP2018188481A (ja) | 2018-11-29 |
| AP2015008720A0 (en) | 2015-09-30 |
| JP2016512824A (ja) | 2016-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151907A1 (es) | Compuestos y usos de estos para la modulacion de la hemoglobina | |
| MX378131B (es) | Compuestos y sus usos para modular la hemoglobina. | |
| MX2015011448A (es) | Compuestos y sus usos para modular la hemoglobina. | |
| CL2015002501A1 (es) | Compuestos y usos de estos para la modulación de la hemoglobina | |
| AR095341A1 (es) | Compuestos y usos para la modulación de hemoglobina | |
| DOP2018000268A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| UY35485A (es) | Compuestos heterocíclicos y usos de los mismos | |
| AR096052A1 (es) | Compuestos y sus usos para la modulación de hemoglobina | |
| AR095340A1 (es) | Compuestos y sus usos para la modulación de hemoglobina | |
| PE20151280A1 (es) | Compuestos y metodos para la modulacion de quinasas y sus indicaciones | |
| CO7101245A2 (es) | Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido | |
| UY35639A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| NI201400081A (es) | Nuevos derivados de indolizina , su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| PE20151982A1 (es) | Derivados de bencimidazolona como inhibidores del bromodominio | |
| AR095342A1 (es) | Piridinas 2,3-sustituidas y su uso para la modulación de hemoglobina | |
| CR20150549A (es) | Compuestos heterocíclicos y sus usos | |
| ECSP14013215A (es) | Compuestos novedosos | |
| MX2013002255A (es) | Moduladores de proteina de notum y metodos de uso. | |
| UY32863A (es) | COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR | |
| EA201270808A1 (ru) | Новые формы рифаксимина и их применение | |
| NI201600015A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| CO6410315A2 (es) | Nuevos anticuerpos anti-alfa5beta1 y sus usos | |
| CY1117745T1 (el) | Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης | |
| UY35653A (es) | Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| UY33490A (es) | Ésteres de quinolina nuevos útiles para el tratamiento de trastornos cutáneos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |